Milestone Pharmaceuticals Inc.: Milestone Pharmaceuticals Enrolls First Canadian Study Participant in ReVeRA-301 Phase 3 Pivotal Trial Evaluating Etripamil Nasal Spray for AFib-RVR
Milestone Pharmaceuticals (MIST) announced the first Canadian patient enrollment in the ReVeRA-301 Phase 3 trial for etripamil nasal spray, targeting atrial fibrillation with rapid ventricular rate (AFib-RVR). The study aims to enroll 150 patients globally, evaluating the 70 mg dose already FDA-approved for PSVT as CARDAMYST.
How this was made
The 30-second read
Why it matters
The enrollment milestone moves the trial closer to a pivotal data read‑out, which could drive a label expansion and revenue growth.
Market read
First enrollment is a material biotech catalyst that may influence MIST's near‑term valuation.
What to watch
Reimbursement pathways and competition from other oral anti‑arrhythmic agents could limit upside.
Background
Milestone's CARDAMYST is already FDA‑approved for PSVT; the ReVeRA‑301 trial seeks a new indication for AFib‑RVR.
Ticker impact
Milestone Pharmaceuticals announced the first Canadian patient enrollment in its Phase 3 ReVeRA-301 trial for etripamil nasal spray.
Potential modest upside as investors price in future data read‑out and possible label expansion.
Clinical‑trial milestones are material for biotech valuations; this is the first Canadian enrollment, a fresh, material development.
Market effects
Advances in atrial‑fibrillation therapy may benefit the broader cardiovascular biotech sector.
Positive signal for Canadian biotech research collaborations.
Potential to affect global investors tracking cardiac‑arrhythmia treatments.
Counterpoint
If the trial faces enrollment delays or safety issues, the stock could face downside pressure.
Key entities
- companyMilestone Pharmaceuticals Inc.
Biopharma developing etripamil nasal spray.
- institutionMontreal Heart Institute
First Canadian site enrolling patients.
